Measurement of clinical and subclinical tumour response using [18F]- fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations

European Journal of Cancer

Volumn 35, Issue 13, 1999, Pages 1773-1782

  Young, H ^a   Baum, R ^b   Cremerius, U ^c   Herholz, K ^c   Hoekstra, O ^d   Lammertsma, A A ^d   Pruim, J ^e   Price, P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Central Hospital Bad Berka   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Drug evaluation; Fluorodeoxyglucose; Medical oncology; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG SCREENING; DRUG UPTAKE; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MEDULLOBLASTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0032757213     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00229-4     Document Type: Article

References (51)

1. Herholz K., Rudolf J., Heiss W.D. FDG transport and phosphorylation in human gliomas measured with dynamic PET. J. Neurooncol. 12:1992;159-165.
2. Wahl R.L., Zasadny K., Helvie M., Hutchins G.D., Weber B., Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography. initial evaluation J. Clin. Oncol. 11:1993;2101-2111.
3. Brown R.S., Wahl R.L. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 72:1993;2979-2985.
4. Brown R.S., Leung J.Y., Fisher S.J., Frey K.A., Ethier S.P., Wahl R.L. Intratumoural distribution of tritiated-FDG in breast carcinoma. correlation with Glut-1 expression and FDG uptake J. Nucl. Med. 37:1996;1042-1047.
5. Minn H., Joensu H., Ahonen A., Klemi P. Fluorodeoxyglucose imaging. a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumours Cancer. 61:1988;1776-1781.
6. Okada J., Yoshikawa K., Itami M.et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma. a comparison with proliferative activity J. Nucl. Med. 33:1992;325-329.
7. Higashi K., Clavo A.L., Wahl R.L. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J. Nucl. Med. 34:1993;414-419.
8. Herholz K., Pietrzyk U., Voges J.et al. Correlation of glucose consumption and tumour cell density in astrocytomas. A stereotactic PET study. J. Neurosurg. 79:1993;853-858.
9. Price P., Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET study group. Eur. J. Cancer. 31A:1995;1924-1927.
10. Woodward H.Q., Bigler R.E., Freed B., Russ G. Expression of tissue isotope distribution. J. Nucl. Med. 16:1975;958-959.
11. Zasadny K.R., Wahl R.L. Standardised uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. variations with body weight and a method for correction Radiology. 189:1993;847-850.
12. Kim C.K., Gupta N.C. Dependency of standardised uptake values of fluorine-18 fluorodeoxyglucose on body size. comparison of body surface area correction and lean body mass correction Nucl. Med. Commun. 17:1996;890-894.
13. Hamberg L.M., Hunter G.J., Alpert N.M., Choi N.C., Babich J.W., Fischmann A.J. The dose uptake ratio as an index of glucose metabolism. useful parameter or over-simplification J. Nucl. Med. 35:1994;1308-1312.
14. Coleman R.E. PET in lung cancer. J. Nucl. Med. 40:1999;814-820.
15. 14C)-deoxyglucose method for measurement of local cerebral glucose utilisation: theory, procedure and normal values in the conscious and anaesthetised albino rat. J. Neurochem. 28:1977;897-916.
16. 18F]-fluoro-2-deoxy-D-glucose. variation of method Ann. Neurol. 6:1979;371-388.
17. Hawkins R.A., Phelps M.E., Huang S.C. Effects of temporal sampling, glucose metabolic rates and disruption of the blood-brain barrier on the FDG model with and without a vascular compartment: studies in human brain tumours with PET. J. Cereb. Blood Flow Metab. 6:1986;170-183.
18. Patlak C.S., Blasberg R.G., Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 3:1983;1-7.
19. Herholz K., Patlak C.S. The influence of tissue heterogeneity on results of fitting non-linear model equations to regional tracer uptake curves. with an application to compartmental models used in positron emission tomography J. Cereb. Blood Flow Metab. 7:1987;214-229.
20. Schmidt K., Lucignani G., Sokoloff L. Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilisation. a re-examination J. Nucl. Med. 37:1996;394-399.
21. 18F]-fluoro-2-deoxy-D-glucose. a comparison of different analytical methods J. Cereb. Blood Flow Metab. 7:1987;161-172.
22. Spence A.M., Muzi M., Graham M.M.et al. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG. analysis of the FDG lumped constant J. Nucl. Med. 39:1998;440-448.
23. 18F]-fluorodeoxyglucose uptake in tumours. kinetic vs steady-state methods with reference to plasma insulin J. Comput. Assist. Tomogr. 17:1993;115-123.
24. Kole A.C., Niewig O.E., Prium J.et al. Standardised uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[11C]tyrosine PET. J. Nucl. Med. 38:1997;692-696.
25. Avril N., Bense S., Ziegler S.I.et al. Breast imaging with fluorine-18-FDG PET. quantitative image analysis J. Nucl. Med. 38:1997;1186-1191.
26. Langen K.J., Baum U., Kops E.et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J. Nucl. Med. 34:1993;355-359.
27. Lindholm P., Minn H., Leskinen-Kallio S., Bergman J., Ruotsalainen U., Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer, a PET study. J. Nucl. Med. 34:1993;6-11.
28. Ishizu K., Nishizawa S., Yonekura Y.et al. Effects of hyperglycemia on FDG uptake in human brain and glioma. J. Nucl. Med. 35:1994;1104-1109.
29. Zimny M., Bares R., Fass J.et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma. a report of 106 cases Eur. J. Nucl. Med. 24:1997;678-682.
30. Fulham M.J., Bruneti A., Aloj H., Ramen R., Dwyer A.J., Di Chiro G. Decreased cerebral glucose metabolism in patients with brain tumours. an effect of corticosteroids J. Neurosurg. 83:1995;657-664.
31. Roelcke U., Blasberg R.G., von Ammon K.et al. Dexamethasone treatment and plasma glucose levels. relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas J. Nucl. Med. 39:1998;879-884.
32. Langen K.J., Roosen N., Kuwert T.et al. Early effects of intra-arterial chemotherapy in patients with brain tumours studied with PET. preliminary results Nucl. Med. Commun. 10:1989;779-790.
33. Rozental J.M., Levine R.L., Nickles R.J., Dobkin J.A. Glucose uptake by gliomas after treatment. Arch. Neurol. 46:1989;1302-1307.
34. De Witte O., Hildebrand J., Luxen A., Goldman S. Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer. 74:1994;2836-2842.
35. Ogawa T., Uemura K., Shishido F.et al. Changes of cerebral blood flow, and oxygen and glucose metabolism following radiochemotherapy of gliomas. a PET study J. Comp. Assist. Tomogr. 12:1988;290-297.
36. O'Reilly S.M., Newlands E.S., Harte R.J.A.et al. Early changes in tumour glucose metabolism may predict and quantify response of gliomas to chemotherapy. a phase II study using temozolomide Proc. Am. Soc. Clin. Oncol. 14:1995;499.
37. Holthoff V.A., Herholz K., Berthold F.et al. In vivo metabolism of childhood posterior fossa tumours and primitive neuroectodermal tumours before and after treatment. Cancer. 72:1993;1394-1403.
38. Haberkorn U., Strauss L., Dimitrakopoulou A.et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J. Nucl. Med. 34:1993;12-17.
39. Jansson T., Westlin J.E., Ahlstrom A., Lilja A., Langstrom B., Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer. a method for early therapy evaluation J. Clin. Oncol. 13:1995;1470-1477.
40. Findlay M., Young H., Cunningham D.et al. Noninvasive monitoring of tumour metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases. correlation with tumour response to fluorouracil J. Clin. Oncol. 14:1996;700-708.
41. Hoekstra O.S., Ossenkoppele G.J., Golding R.et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J. Nucl. Med. 34:1993;1706-1710.
42. Rigo P., Paulus P., Kaschten B.J.et al. Oncological applications of positron emission tomography with fluorine-18-fluorodeoxyglucose. Eur. J. Nucl. Med. 23:1996;1641-1674.
43. 18F-FDG positron emission tomography. prospects for detection and management Eur. J. Nucl. Med. 22:1995;508-513.
44. Van Ginkel R.J., Hoekstra H.J., Pruim J.et al. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced of soft tissue sarcoma. J. Nucl. Med. 37:1996;984-990.
45. Haberkorn U., Strauss L.G., Dimitrakopoulou A.et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumours receiving radiotherapy. J. Nucl. Med. 32:1991;1485-1490.
46. Rozental J.M., Levine R.L., Mehta M.P.et al. Early changes in tumour metabolism after treatment. the effects of stereotactic radiotherapy Int. J. Radiat. Oncol. Biol. Phys. 20:1991;1053-1060.
47. Minn H., Paul R., Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18-fluorodeoxyglucose. J. Nucl. Med. 29:1988;1521-1525.
48. Cremerius U., Effert P.J., Adam G.et al. FDG PET for detection and therapy control of metastatic germ cell tumour. J. Nucl. Med. 39:1998;815-822.
49. Sugawara Y., Zasadny K.R., Barton Grossman H., Isaac R.F., Clarke M.F., Wahl R.L. Germ cell tumor. differentiation of viable tumor, mature teratoma and necrotic tissue with FDG PET and kinetic modelling Radiology. 211:1999;249-256.
50. Brock CS, Young H, O'Reilly SM, et al. Early prediction of response in phase II study using [18F] fluorodeoxyglucose and positron emission tomography: experience with temozolomide and recurrent high grade astrocytomas. Br J Cancer 1999, in press.
51. Minn H., Zasadny K.R., Quint L.E., Wahl R.L. Lung cancer. reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET Radiology. 196:1995;167-173.